Firefly Neuroscience Accepted into NVIDIA Connect Program
11. Februar 2025 07:45 ET
|
Firefly Neuroscience, Inc.
Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform For the first time, Firefly also unveils a new strategic...
Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics
07. Februar 2025 07:30 ET
|
Firefly Neuroscience, Inc.
- University of Waterloo’s Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award - - Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly...
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care
24. Januar 2025 09:00 ET
|
Firefly Neuroscience, Inc.
Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and cognitive change, driving innovation in brain health Company...
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
14. Januar 2025 07:45 ET
|
Firefly Neuroscience, Inc.
KENMORE, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience Closes on Financing of up to $12.4 Million
31. Dezember 2024 09:00 ET
|
Firefly Neuroscience, Inc.
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman
04. Dezember 2024 09:00 ET
|
Firefly Neuroscience, Inc.
TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
14. November 2024 17:30 ET
|
Firefly Neuroscience, Inc.
Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company’s...
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
06. November 2024 09:00 ET
|
Firefly Neuroscience, Inc.
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
25. Oktober 2024 16:10 ET
|
Firefly Neuroscience, Inc.
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
16. Oktober 2024 09:20 ET
|
Firefly Neuroscience, Inc.
TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...